Michael Dybbs
Partner @ Samsara BioCapital
San Mateo, United States
Michael Dybbs is a Series B investor at Samsara BioCapital in San Mateo focused on Biotechnology and Health Care. Michael Dybbs is based out of Palo Alto, California, and is the Partner of Samsara BioCapital. Michael previously worked at New Leaf Venture Partners as a Partner. Michael Dybbs attended the University of California, Berkeley.
- Total investments:
- 13
- Last investment:
- Lead investor:
- 46%
Last updated:
For AI agents: llms.txt
Industries Michael Dybbs invests in
Stages Michael Dybbs invests in
Countries Michael Dybbs invests in
Investment Focus
Industry
- Biotechnology 8 (62%)
- Health Care 5 (38%)
- Medical 4 (31%)
- Therapeutics 3 (23%)
- Biopharma 2 (15%)
Stage
- Series B 5 (38%)
- Series C 3 (23%)
- Series E 2 (15%)
- Series D 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Claris Biotherapeutics
|
Claris Biotherapeutics develops a topical formulation intended to cure corneal wounds, ulcers, and scars. The formulation creates a recombinant hepatocyte growth factor which accelerates the healing process, providing healthcare providers noninvasive therapeutic treatment. | $118M / Series B / Jul 28, 2026 | |
Arcellx
|
Arcellx is a privately held development-stage company founded in 2015 and located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, and responsible patient care. Although our initial clinical focus is cancer therapy, we arecommitted to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease. | $115M / Series C / Apr 13, 2021 | |
Ionpath
|
Ionpath is a developer of an ion beam imaging technology used to provide analysis of tissue biopsies. Its imaging technology surpasses light microscopy to analyze whether the tissues are fresh, frozen, or FFPE that enable healthcare providers to provide a diagnosis of cancer for improving human health. | $18M / Series B / Sep 24, 2020 | |
Nkarta Therapeutics
|
Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile. | $114M / Series B / Sep 04, 2019 | |
Sutro Biopharma
|
Sutro Biopharma is a clinical stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF.Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. | $85.4M / Series E / Jul 26, 2018 | |
Principia Biopharma
|
Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversiblecovalent platform. | $15.3M / Series B / Aug 10, 2015 | |
Advanced Cell Diagnostics
|
Advanced Cell Diagnostics (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. | $22M / Series C / Jun 18, 2015 | |
Dimension Therapeutics
|
Dimension Therapeutics is a gene therapy company focused on developing novel treatments for rare diseases. Their team comprises biotech industry veterans and thought leaders in gene therapy and rare diseases.The company is focused on advancing its platform of gene therapy programs in rare diseases through clinical development, starting with leadprograms in hemophilia, and building out a world-class product engine for adeno-associated virus (AAV) therapeutics.In conjunction with its launch, Dimension has entered into an exclusive license and collaboration with REGENX Biosciences. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV vector technology and related applications. Through its license and collaboration with REGENX, Dimension has acquired preferred access to NAV vector technology and rights within REGENX product programs in multiple rare disease indications. Dimension has completed a Series A financing led by Fidelity Biosciences. | $65M / Series B / Apr 21, 2015 | |
|
Principia Biopharma
|
Principia Biopharma is a private, pre-clinical stage company initially focused on the discovery and development of differentiated small molecule drugs targeting inflammatory/autoimmune diseases as well as cancer. The company expects to submit an IND for its lead program in 2013 and continues to invest in additional programs and its reversiblecovalent platform. | $50M / Series B / Apr 22, 2014 | |
Versartis
|
Versartis is a biotechnology company developing therapeutic proteins for the treatment of endocrine disorders. It develops new therapeutic proteins utilizing the novel half-life extension technology, XTEN. Versartis owns and develops the novel drug candidates that it has licensed from Amunix.Headquartered in Redwood City, California,Versartis' lead program, VRS-317, has recently completed enrollment in a multi-center Phase 1 study in adult patients with growth hormone deficiency. The company is staffed with drug development experts and utilizes external contract services to execute on its product development plans in a capital-efficient manner.The company was founded in December 2008 as a joint venture between Amunix Inc. and Index Ventures. The founders are Jeffrey Cleland, Mark de Boer, Willem Stemmer, Volker Schellenberger, and Joshua Silverman. | $55M / Series E / Feb 19, 2014 | |
| See all 13 investments → | |||
Co-Investors
About Samsara BioCapital
Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotesbiotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.
Samsara BioCapital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Abraham Bassan
Partner
|
|||
|
Michael Dybbs
Partner
|
|||
|
Christian Richard
Head of Public Research
|
|||
Marcos Milla
Venture Partner
|
|||
Srini Akkaraju
Founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michael Dybbs invest in?
Michael Dybbs invests primarily in Biotechnology, Health Care and Medical startups, most often at Series B and Series C stage. Most of the 13 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Michael Dybbs last invest?
The most recent investment recorded for Michael Dybbs closed in Jul 2026. Shizune tracks 13 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
